PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Show other versions (1)

<p>According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” s...

Full description

Bibliographic Details
Main Authors: Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
дабигатрана этексилат
варфарин
антагонисты витамина К
фибрилляция предсердий
фармакоэкономика
клинико-экономический анализ
стоимость-эффективность
Марковское моделирование
Online Access:http://www.rpcardio.ru/jour/article/view/397

Internet

http://www.rpcardio.ru/jour/article/view/397

Similar Items